Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UMPS | P11172 | 2/20 | 1.00 |
| ▸ | PYGL | P06737 | 5/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | BLM | P54132 | 1/20 | 0.39 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 3/20 | 0.37 |
| ▸ | GLA | P06280 | 1/20 | 0.37 |
| ▸ | EIF4E | P06730 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | TOP1 | P11387 | 1/20 | 0.37 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.37 |
| ▸ | THPO | P40225 | 1/20 | 0.37 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pyrazofurin SCHEMBL11835057 | 1.00 | UMPS (1.00) | UMPSPYGLSMN1; SMN2ALDH1A1TSHR | |
| Pyrazofurin SCHEMBL11826269 | 1.00 | UMPS (1.00) | UMPSPYGLSMN1; SMN2ALDH1A1TSHR | |
| Pyrazofurin SCHEMBL27539623 | 1.00 | UMPS (1.00) | UMPSPYGLSMN1; SMN2ALDH1A1TSHR | |
| Pyrazofurin SCHEMBL11835064 | 1.00 | UMPS (1.00) | UMPSPYGLSMN1; SMN2ALDH1A1TSHR | |
| Pyrazofurin SCHEMBL4860 | 1.00 | UMPS (1.00) | UMPSPYGLSMN1; SMN2ALDH1A1TSHR | |
| Pyrazofurin SCHEMBL4861 | 1.00 | UMPS (1.00) | UMPSPYGLSMN1; SMN2ALDH1A1TSHR | |
| Pyrazofurin SCHEMBL29370114 | 1.00 | UMPS (1.00) | UMPSPYGLSMN1; SMN2ALDH1A1TSHR | |
| Pyrazofurin SCHEMBL11726623 | 0.99 | UMPS (0.97) | UMPSPYGLSMN1; SMN2ALDH1A1TSHR | |
| Pyrazofurin SCHEMBL10584948 | 0.95 | UMPS (0.90) | UMPSPYGLSMN1; SMN2ALDH1A1TSHR | |
| SCHEMBL11826483 | 0.78 | UMPS (0.63) | UMPSALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220218731-A1 | COMBINATION THERAPIES FOR CANCER TREATMENT | CLEAR CREEK BIO INC (US) | 2022-07-14 | — | — | US | disclosed |
| US-20210315880-A1 | METHODS OF TREATING VIRAL INFECTIONS USING INHIBITORS OF NUCLEOTIDE SYNTHESIS PATHWAYS | CLEAR CREEK BIO INC (US) | 2021-10-14 | — | — | US | disclosed |
| US-20210308117-A1 | METHODS OF TREATING VIRAL INFECTIONS USING INHIBITORS OF NUCLEOTIDE SYNTHESIS PATHWAYS | CLEAR CREEK BIO INC (US) | 2021-10-07 | — | — | US | disclosed |
| US-20210290651-A1 | METHODS OF TREATING VIRAL INFECTIONS USING INHIBITORS OF NUCLEOTIDE SYNTHESIS PATHWAYS | CLEAR CREEK BIO INC (US) | 2021-09-23 | — | — | US | disclosed |
| US-20190290635-A1 | METHODS OF TREATING BRAIN CANCER USING AGENTS THAT ALTER ACTIVITY OF A METABOLIC PATHWAY | Clear Creek Bio, Inc. | 2019-09-26 | — | — | US | disclosed |
| US-20190290892-A1 | METHODS OF DETERMINING DOSING OF A THERAPEUTIC AGENT BASED ON MEASURED LEVELS OF A METABOLITE | Clear Creek Bio, Inc. | 2019-09-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210315880-A1 | METHODS OF TREATING VIRAL INFECTIONS USING INHIBITORS OF NUCLEOTIDE SYNTHESIS PATHWAYS | DHODH, DHFR, DPYD | UMPS 64/4885PYGL 2456/4885SMN1; SMN2 2783/4885 |
| US-20190290635-A1 | METHODS OF TREATING BRAIN CANCER USING AGENTS THAT ALTER ACTIVITY OF A METABOLIC PATHWAY | DHODH, IDH2, DLD | UMPS 796/4885PYGL 1747/4885SMN1; SMN2 3467/4885 |
| US-20210290651-A1 | METHODS OF TREATING VIRAL INFECTIONS USING INHIBITORS OF NUCLEOTIDE SYNTHESIS PATHWAYS | DHODH, DHFR, DPYD | UMPS 64/4885PYGL 2456/4885SMN1; SMN2 2783/4885 |
| US-20210308117-A1 | METHODS OF TREATING VIRAL INFECTIONS USING INHIBITORS OF NUCLEOTIDE SYNTHESIS PATHWAYS | DHODH, DHFR, DPYD | UMPS 64/4885PYGL 2456/4885SMN1; SMN2 2783/4885 |
| US-20220218731-A1 | COMBINATION THERAPIES FOR CANCER TREATMENT | PCK2, PC, FOLR2 | UMPS 1839/4885PYGL 871/4885SMN1; SMN2 4169/4885 |
| US-20190290892-A1 | METHODS OF DETERMINING DOSING OF A THERAPEUTIC AGENT BASED ON MEASURED LEVELS OF A METABOLITE | IDH2, NQO1, TXNRD2 | UMPS 1605/4885PYGL 780/4885SMN1; SMN2 1573/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.